A Transformational Year: ImaginAb expands Pipeline to includ

LOS ANGELES, Oct. 4, 2022 /PRNewswire/ -- ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and next generation therapeutic radiopharmaceuticals

Related Keywords

China , Boston , Massachusetts , United States , Australia , South Korea , United Kingdom , Turkey , America , Kostenloser Wertpapierhandel , Astra Zeneca , Ian Wilson , Society Of Immunotherapy Cancer , Ibm , Boehringer Ingelheim , Prnewswire Imaginab Inc , Melanoma Research Alliance , Pfizer , University Of California Davis , Dongchengpharmaceutical Group , Memorial Sloan Kettering Cancer Center , Immunopet Partnership Agreements , Radiopharmaceutical Therapies , Biologics License Application , Inclusion Body Myositis , Merkel Cell , Renal Cell , Non Small Cell Lung Cancer , California Davis , Imaging Endpoints , Territorial Licensing Agreement , Manufacturing Agreements , North America , Pharmaceutical Therapy , Chief Executive Officer , Transformational , Ear , Imaginab , Xpands , Pipeline , Nclude , Radiopharmaceutical , Therapies , Centers , Multiple , Partnerships , Drives , Forward , Development , Investigational , Mmunopet , Agent ,